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Abstract 
 
Recent advances in nanotechnology have offered a wealth of new opportunities for the design of 
new therapy of cancer creating new drug delivery systems. It has been possible to produce 
nanoparticles, in particular polysaccharide-based ones, to allow the site-specific delivery of 
drugs and to improve the pharmacokinetic profile of numerous compounds.  
Throughout this work, the system of chitosan (CS)-based nanocarriers produced by 
coacervation with gum arabic (GA) is presented. The main experiments were focused on the 
encapsulation of bortezomib (BTZ) and Gold nanoparticles (GoldNP) in the CS/GA system. 
Completing this work, chemopreventive agents were encapsulated in the same system; catechins 
(EGCG) and vitamin D; accompanied by Gold nanoparticles too.  
All the different produced nanoparticles produced were within the size range of 200-400 nm, 
presenting a low polydispersity index, a positive zeta potential and a spherical shape. The 
different formulations attained a medium bortezomib encapsulation efficiency of 61%, a EGCG 
of 40%, a vitamin D of 83% and a Gold nanoparticles encapsulation efficiency of nearly 100%. 
The encapsulation efficiency was increased for bortezomib, EGCG and vitamin D when the 
particles were coated with polysorbate 80 which acted as a stabilizing agent.  
Studies of release for bortezomib and Gold nanoparticles system were carried in water and PBS, 
showing a biphasic pattern with an initial burst, attributed to the entrapped and surface adsorbed 
drug, followed by slower release. In water, not all release from nanoparticles was appreciated 
after long time, besides in PBS it was noted that the nanoparticles were biodegradable. 
In addition, bortezomib-loaded nanoparticles were tested by in vitro cytotoxic studies. The 
cytotoxic effect was studied in cancer pancreatic cell line compared to normal pancreatic cell 
line. They have shown how less concentration of encapsulated bortezomib was needed to have 
the same effect as free bortezomib in cancer cells. Furthermore, encapsulated bortezomib just 
inhibited the cell growth as opposed to death of cells produced by free bortezomib, at higher 
concentrations.         
According to the results, it is possible to conclude that bortezomib and GoldNP CS/GA 
nanoparticles is a future alternative to replace the treatment with bortezomib of tumors. 
Continuing the work with encapsulated EGCG and vitamin D showed also promising results.  
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1. Introduction 
 
1.1. Motivation  
 
Cancer is a complex problem. Worldwide, one in eight deaths is due to cancer. When countries 
are grouped according to economic development, cancer is the leading cause of death in 
developed countries and the second leading cause of death in developing countries [1]. Cancer 
treatment includes chemotherapy, radiation, and surgery. Focusing in chemotherapy, the main 
actually problems are due to non specificity of many anticancer drugs. Which are related to side 
effects on normal tissues or incomplete eradication of the cancer. The kinds of side effects and 
how severe they are depend on the type and dose of the anticancer drug.  
The international effort to understand and control it involves researchers trained in many 
branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical 
and physical sciences, with the purpose to integrate the cancer biology to the engineering. In 
this direction, in recent years, the nanotechnology has emerged on cancer research. 
Nanotechnology is being applied to cancer in two broad areas: the development of nanovectors, 
such as nanoparticles, which can be loaded with drugs or imaging agents and then targeted to 
tumors, as well as nanosensor devices for detecting the cancer. Combined, such technologies 
could lead to earlier diagnosis and directly and selectively therapies at cancerous cells. 
 
1.2. Main objectives 
 
The objective of this work is to develop polysaccharide nanoparticles with the purpose of 
encapsulating an anticancer drug with Gold nanoparticles. These nanoparticles will be produced 
with the aim of reducing the anticancer drug concentration in order to reduce toxic side effects, 
as well as, be delivered and released specifically into cancer cells. 
Firstly, chitosan/gum Arabic nanoparticles will be produced by the electrostatic interactions 
between both polymers with the goal of characterizing the most suitable formulation. 
Afterwards, bortezomib and GoldNP will be encapsulated in the CS/GA nanoparticles in order 
to characterize and study them for their delivery and release into pancreatic cancer cells and 
pancreatic normal cells, compared with the free bortezomib action. 
Finally, the work will be completed with the encapsulation of chemopreventive agents, EGCG 
and vitamin D, with gold nanoparticles in the same CS/GA system.  
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1.3. Thesis organization 
 
This thesis is divided in 5 chapters.  
In Chapter 1 it is introduced the main issue and motivation to develop this nanosystem as well 
as it is set the main objective of this work. 
Then, the state of the art is defined in Chapter 2, which contains the studies that have been 
developed so far on the nanoparticles applied for anticancer drug delivery, particularized for 
chitosan-based ones. The other main molecules of this thesis are also defined in this chapter. 
Chapter 3 describes the reagents and methods followed in the different experiments. 
Chapter 4, the main one, presents the experimental results. Starting for the characterization of 
bare CS/GA system, continuing for the encapsulation of anticancer drug, bortezomib together 
with gold nanoparticles and finally, the encapsulation of the chemopreventive agents.    
The end of this thesis is Chapter 5 with the main conclusions and future work perspectives.  
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2. State of the Art 
 
2.1. Cancer therapy problematic 
 
Cancer is one of the most devastating diseases and it involves various genetic alterations and 
cellular abnormalities. This complexity and heterogeneity promote the aggressive growth of 
cancer cells leading to significant morbidity and mortality in patients [2].  
There is a lack of thorough cure for cancers. A worthy goal at the present is to develop 
treatments that produce remission and/or palliation. Effective treatments include surgery, 
radiotherapy, chemotherapy, hormone therapy and immunotherapy. Each of these treatment 
modalities has advantages and disadvantages, and their combination is usually needed to 
produce the most effective results [3]. 
Chemotherapy for cancer, however, is understood in a narrower sense of using 
chemotherapeutical agents directed at killing or controlling the cancer cells [3]. This purpose is 
to kill the tumor cells as these cells are more susceptible to the actions of these drugs and 
methods because of their growth at a much faster rate than healthy cells [4]. It carries a high risk 
due to drug toxicity. The most effective drugs tend to be more toxic [3].  
As cancer fighting drugs are toxic to both tumor and normal cells, the efficacy of chemotherapy 
is often limited by important side- effects [5]. Such symptoms often compromise patients' 
quality of life and may lead to the decision to postpone or even reject future, potentially life-
saving treatments [6]. 
Even the effectiveness of chemotherapy depends on many factors, such as the drug(s) used, the 
condition of the patient or the dosage and its form and schedule; the most common obstacles 
associated with conventional cancer [3] drug are the low bioavailability and limited accessibility 
of drug to tumor tissues, which therefore requires a higher dose, leading to intolerable 
cytotoxicity [7]. Besides the lack of specificity, which causes, as well, significant damage to 
non-cancerous tissues, resulting in undesirable side effects [8].  
In all cases, the effectiveness of the treatment is directly related to the treatment’s ability to 
target and to kill the cancer cells while affecting as few healthy cells as possible. The degree of 
change in the patient’s quality of life and eventual life expectancy is directly related to this 
targeting ability of the treatment. New therapeutic options and the goal of these are to increase 
survival time and the quality of life for cancer patients [4]. 
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2.2. Nanoparticles as anticancer drug carriers 
 
The convergence of nanotechnology and anticancer drug discovery can offer solutions to many 
of the inherent problems associated with conventional anticancer therapeutics [8] by offering 
smart drug delivery systems, which allows real progresses to achieve temporal and spatial site-
specific delivery [9]. Nanotechnology has a crucial role in cancer therapy regarding the use of 
different nanocarriers such as liposomes, carbon nanotubes, polymer–drug conjugates and NPs 
[7]. 
According to the preparation process and materials, nanoparticles, nanospheres or nanocapsules 
can be obtained. Unlike nanospheres (matrix systems in which the drug is dispersed throughout 
the particles), nanocapsules are vesicular systems in which the drug is confined to an aqueous or 
oily cavity surrounded by a single polymeric membrane. Nanocapsules may, thus, be considered 
as a reserve system [10]. 
Nanoparticles are typically in the range of 10 to 1000 nm diameter and the drug is dissolved, 
entrapped, encapsulated or attached to a NP matrix [8, 11]. NP offer the ability to increase the 
solubility and bioavailability of attached drugs [12] convert insoluble or poorly soluble drugs 
into soluble suspensions, thus eliminating the need for toxic organic solvents [8].  
A strategy could be to associate antitumor drugs with colloidal nanoparticles, which generally, 
but not necessarily, made of polymers (biodegradable or not) [13]. It offers better 
pharmacokinetic parameters with the aim to overcome non-cellular and cellular based 
mechanisms of resistance. As well, to increase selectivity of drugs [7, 5] by effectively deliver 
the drug to a target site, while reducing their toxicity towards normal tissues. Thus, increase the 
therapeutic benefit while minimizing side effects [11]. 
The incorporation of anticancer drugs into nanoparticles not only has the potential to decrease 
their adverse cytotoxic effects, but also in many cases may increase the accumulation of the 
drug in the tumor vasculature, a phenomenon known as enhanced permeability and retention 
(EPR) [13,14]. 
The controlled release (CR) of pharmacologically active agents to the specific site of action at 
the therapeutically optimal rate and dose regimen has been a major goal in designing such 
devices. NPs help to increase the stability of drugs, while minimizing side effects [15].  
In recent years, mainly biodegradable polymeric NPs have attracted considerable attention as 
potential drug delivery devices in view of their applications in the CR of drugs [11]. These NPs 
can be targeted to specific sites by surface modifications using different ligands to the receptors 
that are highly overexpressed on the target cancer cells [7]. 
Furthermore, a controlled release of the drug content inside of the tumor interstitium may be 
achieved by controlling the nanoparticle structure: polymers used and the way by which the 
drug is associated with the carrier (adsorption or encapsulation). If designed properly, 
nanoparticles may act as a drug vehicle able to target tumor tissues or cells, to a certain extent, 
while protecting the drug from premature inactivation during its transport [5]. 
Moreover, a general conclusion from these detailed studies was that the size of the particles has 
a key role in their transport across epithelia. This observation encouraged researchers to develop 
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new types of nanoparticles made of biodegradable materials with the final goal of using them as 
drug carriers across mucosal surfaces [18].  
Nanocarriers can protect a drug from degradation by evading the macrophages of the 
reticuloendothelial system (RES) and, thus, a high blood circulation profile enables transport 
through biological barriers, increasing the availability of drug at the targeted intracellular 
compartments reducing the toxicity and other side-effects associated with conventional drug 
delivery [7]. 
Nanoparticles may be administered by different routes. These include intravenous, 
intramuscular, and subcutaneous injection, as well as peroral, ophthalmic and transdermal 
administration [16]. Nanoparticles like other colloidal drug carriers are able to pass through all 
capillaries after injection into the blood stream [17]. 
To sum up, in general, nanocarriers may (i) protect a drug from degradation, (ii) enhance drug 
absorption by facilitating diffusion through epithelium, (iii) modify pharmacokinetic and drug 
tissue distribution profile, and/or (iv) improve intracellular penetration and distribution [9]. 
As example, Doxil® and Abraxane® are two nanotechnology-based anticancer drug 
formulations that are approved by the United States Food and Drug Administration (FDA) for 
ovarian and metastatic breast cancer, respectively [8]. Doxil® is a liposomal formulation of 
doxorubicin [19]. Abraxane® (Abraxis) is an albumin-bound nanoparticle formulation of 
paclitaxel [20].  
 
 
2.3. Polysaccharide-based nanoparticles  
 
In recent years, polymer NPs have attracted considerable attention as potential drug delivery 
devices in view of their application in the field of cancer [7]. Polysaccharides are biocompatible, 
biodegradable and stable [21]. Natural polymers are also non-toxic [22]. 
Generally, nanoparticles based on hydrophobic polymers, uncharged and positively charged, 
provide an affinity to follicle-associated epithelia as well as to absorptive enterocytes. In 
contrast, nanoparticles based on hydrophilic polymers, negatively charged, show a strong 
increase in bioadhesive properties and are absorbed by both M cells and absorptive enterocytes. 
A combination of both nanoparticle' surface charges and increased hydrophilicity of the matrix 
material seem to affect the gastrointestinal uptake in a positive sense [23]. 
Depending on the physicochemical characteristics of a drug, it is now possible to choose the 
best method of preparation and the best polymer to achieve an efficient entrapment of the drug 
[23, 24]. In addition, polysaccharides can be used either to prepare nanoparticles, as coating 
materials or to form polysaccharide-drug conjugates [25,26]. 
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2.3.1. Chitosan nanoparticles 
 
The most promising biopolymer as ideal drug carrier for the controlled drug delivery is 
Chitosan (CS) [27]. Chitosan is obtained by alkaline N-deacetylation of chitin [28]. Chitin, is 
the second most abundant biopolymer isolated from insects, crustacea such as crab and shrimps 
as well as fungi [29].  
 
However, applications of chitin are limited compared to CS because chitin is chemically inert. 
Acetamide group of chitin can be converted into amino group to give CS, which is carried out 
by treating chitin with concentrated alkali solution. Chitin and CS represent long-chain 
polymers having molecular mass up to several million Daltons [30]. 
 
The deacetylation leads to poly(α1,4-D-glucosamine) or so called chitosan [29] Chitosan is a 
renewable biomaterial, a functional and basic linear polysaccharide [31]. It is a heterogeneous 
binary polysaccharide that consists primarily of N-acetyl-D-glucosamine and D-glucosamine 
randomly distributed and lined units. The latter residue is responsible for its cationic charge at 
acidic pH values [28]. 
 
 
Figure 1. Chemical structure of Chitosan  
 
 
 
Commercially available CS has an average molecular weight ranging between 3800 and 20,000 
Daltons and is 66% to 95% deacetylated [30]. The degree of deacetylation (DD) and molecular 
weight of chitosan have the greatest influence on its physical and chemical properties, including 
i) emulsification capacity, ii) aggregation activity, iii) rheological, iv) and solution and v) 
physicochemical properties.  
 
A limiting factor in the application of chitosan is its low solubility in aqueous media at neutral 
and alkaline conditions and in most organic solvents [31]. However the, pH, and ionic strength 
determine also the properties of chitosan [32]. The pKa value of the glucosamine segments is 
6.3-7.35 At low pH and low ionic strength, the intrinsic viscosity of chitosan increases rapidly, 
due to strong electrostatic segment-segment repulsion, adopts an extended conformation, and 
the rotational flexibility of its chains are relatively large for a polysaccharide polyelectrolyte 
[28].  
 
The primary amine groups render special properties that make CS very useful in pharmaceutical 
and food applications. Compared to many other natural polymers, chitosan has a positive charge 
and is mucoadhesive [33]. Chitosan, being a cationic polysaccharide in neutral or basic pH 
conditions, contains free amino groups and hence, is insoluble in water. In acidic pH, amino 
groups can undergo protonation thus, making it soluble in aqueous solutions [30].  
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Solubility of CS depends upon the distribution of free amino and N-acetyl groups [34]. Usually 
1–3% aqueous acetic acid solutions are used to solubilize CS. In addition, it has good adhesion, 
coagulation ability, and immunostimulating activity [30]. 
 
Chitosan is biocompatible with living tissues since it does not cause allergic reactions and 
rejection. It breaks down slowly to harmless products (amino sugars), which are completely 
absorbed by the human body [35]. Chitosan degrades under the action of ferments, it is nontoxic 
and easily removable from the organism without causing concurrent side reactions. It possesses 
antimicrobial property and absorbs toxic metals like mercury, cadmium, lead, etc [30].  
 
With excellent biocompatible and biodegradable properties, Chitosan has been used extensively 
in the pharmaceutical industry as drug delivery system [27]. Moreover, chitosan has been 
extensively investigated for its potential as a permeation enhancer across intestinal epithelium 
for peptides and proteins [36]. The mucoadhesive property of chitosan is mediated by its ability 
to spread over the mucus layer and additionally its positive ionic interactions with the negative 
charges of the cell surface membranes [37]. 
 
Chitosan nanoparticles obtained by formation of a spontaneous complex between chitosan and 
polyanions have small diameters (200–500 nm) and show a quasi spherical shape under 
transmission electron microscopy [23].  
 
Chitosan has many advantages, particularly for developing micro/nanoparticles. These include: 
its ability to control the release of active agents; it avoids the use of hazardous organic solvents 
while fabricating particles since it is soluble in aqueous acidic solution; it is a linear polyamine 
containing a number of free amine groups that are readily available for crosslinking; its cationic 
nature allows for ionic crosslinking with multivalent anions: it has mucoadhesive character, 
which increases residual time at the site of absorption, and so on.  
 
Chitin and CS have very low toxicity; LD50 of CS in laboratory mice is 16 g/kg body weight, 
which is close to sugar or salt [30].  
 
Various methods for producing chitosan nanoparticles are described in the literature [38,39]. 
Chitosan nanoparticles have been developed to encapsulated proteins such as bovine serum 
albumin, tetanus and diphtheria toxic, vaccines, anticancer agents, insulin, and nucleic acids. 
Chitosan considerably enhanced the absorption of peptides such as insulin [23]. 
 
 
 
2.3.2. Gum Arabic nanoparticles 
 
 
Gum Arabic (GA) (Acacia) is a negatively charged polysaccharide. Biocompatible and 
biodegradable [29] polyelectrolyte that is widely used in the industry due to its high solubility 
and low viscosity at high concentrations, and good emulsifying and microencapsulating 
properties [28,40]. It is mainly used in oral and topical pharmaceutical formulation as a 
suspending and emulsifying agent [29]. 
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It is an arabinogalactan composed of three distinct fractions with different protein contents and 
different molecular weights.[41] The composition analysis of GA reveals the presence of a main 
galactan chain carrying heavily branched galactose/arabinose side chains.  
 
The carbohydrate moiety is composed of D-galactose (40% of the residues), L-arabinose (24%), 
L-rhamnose (13%), and two types of uronic acids, responsible for the polyanionic character of 
the gum, D-glucuronic acid (21%) and 4-O-methyl-Dglucuronic acid (2%). It has been 
suggested that this polysaccharide has a “wattle blossom”-type structure with a number of 
polysaccharide units linked to a common polypeptide chain.[42] This feature is responsible for 
its good surface activity and viscoelastic film-forming ability [28,43].  
 
 
 
Figure 2. Chemical structure of Gum Arabic  
 
 
The GA molecule is somewhat globular, but the openness of its structure and its possible 
existence in a coiled form are possible and, to a degree, dependent on the amount of ionic 
dissociation of the uronic acid units or their salts. In the normal salt form at near neutral pH, 
these carboxyl groups will be largely dissociated, and the resulting Coulombic repulsion of the 
negatively charged carboxylate groups will cause the molecule to assume an open, 
highly charged, expanded structure [44]. 
 
Nevertheless, it has been reported that gum Arabic does not provide long-term stability against 
oxidation to monoterpenes and orange oil [28]. So, an interesting research topic would be to 
investigate its interactions with other biopolymers to improve its barrier properties against 
oxidation.  
 
On the other hand, chitosan is extensively used in the food industry because it forms 
strong, flexible, clear films that exhibit good barrier properties against oxygen [45]. Thus, the 
combined use of gum Arabic with chitosan could provide an inter-biopolymer electrostatic 
complex that could form strong viscoelastic films around oil droplets and provide them with 
good barrier properties against oxidation. 
 
In addition the interaction between gum arabic and chitosan is starting to be exploited in a way 
to enhance the protein delivery [31]. This interaction between two oppositely charged polymers 
due to electrostatic forces is called polyelectrolyte complexation (PEC). When there is 
electrostatic attraction between two charged polysaccharides and one of them is not a strong 
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polyelectrolyte, it may occur complex coacervation. Gum arabic is negatively charged but, even 
though it presents some carboxylate groups, it is not highly charged. Besides, coacervation is 
highly influenced by the pH and ionic strength, and also by the polymer weight ratio, total 
concentration, flexibility and distribution, in a lower extent [31,46]. 
 
 
2.4. Polysaccharides as coating materials  
  
Despite the promising results obtained with the first-generation of drug nanocarrier systems, 
their usefulness is limited by their rapid blood clearance and recognition by the monocyte 
phagocytosis system (MPS) [11]. Surface modified colloidal carriers such as nanoparticles are 
able to modulate the biodistribution of the loaded drug and also to control the absorption of 
drugs administered by different routes [47]. 
 
The medical applications, mainly in imaging cancer, of polysaccharide-coated nanoparticles are 
presented, including their abilities to increase the blood circulation time and to target specific 
tumor tissues. It has been shown that these coatings allow also to improve drug absorption via 
nasal or ocular pathways, due the mucoadhesive and/or permeability enhancer properties of the 
polysaccharides [47,48]. 
 
It seems that the coating acts as a barrier to microbial contamination, and thus improved 
survival prospects of the coated cells [49]. In another study, the coating is performed to protect 
donor mammalian cells against antibodies and cytotoxic cells of the host immune system, 
allowing the transplantation of cells in the absence of immunosuppression [49]. 
The most promising results were obtained by coating particles with hydrophilic surfactants, 
which significantly altered pharmacokinetics and body distribution of nanoparticles. 
Physicochemical studies have shown that coating of colloidal particles with block copolymers 
induced a steric repulsion effect, minimizing the adhesion of particles to the surface of 
macrophages, which in turn resulted in the decrease of phagocytic uptake and in significantly 
higher levels in the blood and non-RES organs, i.e. brain, intestine or kidneys [50].  
Previous studies with different surfactants, for a delivery across the blood brain barrier, showed 
that coating of nanoparticles with surfactants resulted in the uptake by these cells and that 
polysorbate 80 (Tween 80) was the most effective [50]. 
 
2.4.1. PEGylated nanoparticles 
 
For a number of applications, the surfaces of nanoparticles have to be highly hydrophilic and 
able to prevent protein adsorption [47]. Poly Ethylene Glycol (PEG) has often been used as a 
hydrophilic polymer to coat nanoparticles [50]. Nevertheless, PEG only delays but does not 
abolish the capture of these nanoparticles by the monocyte phagocytosis system (MPS) [47,51]. 
However, their blood circulation time was dramatically increased compared to uncoated 
nanoparticles [50].  
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Pegylated nanoparticles have circulation times compatible with the passive targeting of tumors 
or inflammatory tissues, where advantage is taken of an increased vascular permeability [51]. In 
order to achieve an active targeting towards these tissues, specific ligands have to be attached to 
their surface to enable molecular recognition.  
Even so, chemical coupling of such ligands is often difficult, because of the absence of reactive 
groups at the surface of pegylated carriers [47,52]. Moreover, the covalent linkage of a specific 
ligand for active targeting onto the surface of PEG-coated nanoparticles is not easy from a 
chemical point of view [47,52].  
This is one of the reasons why polysaccharide coatings have been considered as an alternative to 
the PEG coatings. Additionally, oligo and polysaccharides may achieve active targeting per se 
since they have specific receptors in certain cells or tissues [53].  
Moreover, they constitute an important class of physiological materials. They display well-
documented biocompatibilities and biodegradabilities, which are the basic characteristics for 
polymers used as biomaterials [54] and have several properties (such as antiviral, antibacterial, 
antitumoral) not found in other natural polymers [47]. Besides, polysaccharides are involved in 
cell surface properties including tissue addressing and transport mechanisms.  
 
 
2.5. Polysaccharide-drug nanoparticles 
 
A successful NP system may be the one, that has a high loading capacity to reduce the quantity 
of the carrier required for administration. Drug loading into the NPs is achieved by two 
methods: one, by incorporating the drug at the time of NP production or secondly, by adsorbing 
the drug after the formation of NPs by incubating them in the drug solution. It is thus evident 
that a large amount of drug can be entrapped by the incorporation method when compared 
to the adsorption [49].  
 
Drug release from NPs and subsequent biodegradation are important for developing the 
successful formulations. The release rates of NPs depend upon: (i) desorption of the surface 
bound /adsorbed drug; (ii) diffusion through the NP matrix; (iii) diffusion (in case of 
nanocapsules) through the polymer wall; (iv) NP matrix erosion; and (v) a combined erosion / 
diffusion process [11].  
 
 
2.5.1. Bortezomib 
 
Bortezomib, commercial name Velcade
®
 (formerly PS- 341), is a modified dipeptidyl boronic 
acid. The product is provided as a mannitol boronic ester, which, in reconstituted form, consists 
of the mannitol ester in equilibrium with its hydrolysis product, the monomeric boronic acid. 
The drug substance exists in its cyclic anhydride form as a trimeric boroxine. 
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Bortezomib has the following chemical structure in Figure 3.  
 
Figure 3. Chemical structure of Bortezomib [SelleckChem, 2012] 
The molecular weight is 384.24 mg/mol. The molecular formula is C19H25BN4O4. The solubility 
of bortezomib in water is practically zero, but it is soluble in DMSO and ethanol.  
Bortezomib is the first of a new class of drugs known as Proteasome inhibitors [55].  
Proteasome inhibitors are novel antitumor agents with preclinical evidence of activity against 
hematological malignancies and solid tumors. Bortezomib is the first proteasome inhibitor to be 
approved for clinical use [56] which has demonstrated impressive antitumor activity and 
manageable toxicities in Phase I and II trials both as a single agent, and in combination with 
other drugs. It has been approved recently by the Food and Drug Administration for therapy of 
patients with multiple myeloma who have received at least two prior regimens and progressed 
on the last of these [57]. 
The proteasome plays a pivotal role in the cellular housekeeping by eliminating mutant, 
misfolded, and damaged proteins. Moreover, the proteasome is involved in the targeted 
elimination of regulatory proteins, such as transcription factors, signaling molecules, and cell 
cycle inhibitors.  
The inhibition of the proteasome results in the abnormal accumulation of many intracellular 
proteins, thereby disrupting cellular homeostasis. Thus, cells undergo cell cycle arrest or 
programmed cell death. The observation that tumor cells are more sensitive to proteasome 
inhibition than normal cells led to propose the proteasome as a novel target for cancer treatment 
[58]. 
More specifically, Bortezomib is a selective and reversible proteasome inhibitor that results in a 
wide range of molecular sequels, including stabilization of cell cycle regulatory proteins, 
inhibition of nuclear factor-nB activation, induction of apoptosis, and override of Bcl-2 
resistance and antiangiogenesis [58]. 
Bortezomib is actually used to treat patients with multiple myeloma. The clinical picture is 
characterized by paresthesias, numbness and pain affecting lower more than upper extremities 
[55]. 
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2.5.2. EGCG 
 
Green tea has been shown to have cancer preventive activity in a variety of organ sites in animal 
models. Among the green tea constituents, epigallocatechin-3-gallate (EGCG) is the most 
abundant and most active constituent [59]. There is considerable evidence that catechins, the 
active ingredient present in tea, have anticancer activity against a variety of cancers.  
 
The chemical structure of EGCG is shown in Fig. 4. 
 
Figure 4. Chemical structure of EGCG [SelleckChem, 2012] 
 
The molecular weight is 458.37 mg/mol. The molecular formula is C22H18O11. The solubility of 
EGCG in water is low, but in DMSO and ethanol it presents higher solubility.  
 
EGCG is also the most active in inhibiting experimental carcinogenesis and related reactions. 
Many mechanisms for the anticancer activities of EGCG have been proposed based mainly on 
studies in cell lines [60]. EGCG has been reported to inhibit mitogen activation protein kinases, 
the activation of activator protein-1, and cell transformation [59,61].  
EGCG has also been shown to cause inhibition of growth factor receptor phosphorylation. As 
well as, induce apoptosis, inhibit DNA methyltransferase activity, and inhibit aberrant 
arachidonic acid metabolism [59]. 
A recent study, demonstrated that encapsulation of EGCG in biodegradable polylactic acid–
polyethylene glycol (PLA–PEG) nanoparticles enhances the tumor growth suppressive 
properties of EGCG [62, 63] PLA–PEG nanoparticles incorporating EGCG repressed the 
growth of prostate cancer cells in vitro, with decreased IC50 values against prostate cancer cells 
as compared to non-encapsulated EGCG [62]. 
Nanoparticle EGCG was also better at inducing apoptosis and inhibiting angiogenesis as 
compared to non-encapsulated EGCG [63]. Importantly, administration of nanoparticle EGCG 
strongly repressed the tumorigenicity of prostate cancer cells in nude mice, resulting in very 
slow growth kinetics of prostate tumor xenografts. These results highlight the therapeutic 
potential of nano-encapsulated EGCG for the prevention and treatment of cancer [62].   
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2.5.3. Vitamin D 
 
Vitamin D is a seco-steroid hormone and has two main chemical forms: D2 and D3. The first is 
vitamin D3 (cholecalciferol), which is synthesized in the skin after light exposure and displays 
several chemical structures, such as, Calciol, Calcidiol and Calcitriol. Calciol is the 
unhydroxylated and inactive form. Calcidiol is the monohydroxylated and blood circulating 
form (25-hydroxyvitamin D3). Calcitriol is the dihydroxylated and active form (1,25-
dihydroxyvitamin D3) [64].  
Figure 5 shows the chemical structure of Calcitriol.  
 
Figure 5. Chemical structure of Calcitriol [SelleckChem, 2012] 
 
The molecular weight is 416.64 mg/mol. The molecular formula is C27H44O3. The solubility of 
Calcitriol in water is practically nil, but it is soluble in DMSO and ethanol.  
 
Calcitriol displays different actions. First, it controls calcium and phosphorus homeostasis, 
intestinal transport, bone metabolism and renal calcium reabsorption, as well as blood pressure 
and insulin secretion. In enterocytes, it combines to its cellular receptor and regulates calcium 
and phosphorous absorption [65]. Second, it regulates immune system and controls cell 
differentiation The second chemical form is vitamin D2 (ergocholecalciferol). It is formed after 
irradiation of ergosterol [64,66].  
In humans, vitamin D2 potency is less than the third of vitamin D3. Once released from food 
matrix, vitamin D is included in mixed micelle, like other lipophilic components, and enters in 
enterocytes via passive diffusion through an unsaturable mechanism [67]. Afterwards, it is 
included in chylomicrons and activated in liver [64].  
Vitamin D as other liposoluble vitamins (A, E and K) has many benefits on health. At 
pharmacological doses, they can be used to treat skin diseases, several types of cancer or 
decrease oxidative stress [64]. 
Different studies shown that Vitamin D plays a variety of biologic roles that potentially reduce 
cancer incidence and promote survival, including suppressing tumor progression by reducing 
cell proliferation and stimulating apoptosis and cell differentiation. 
For next chapters of this work, Calcitriol is referred as Vitamin D.  
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2.6. Gold Nanoparticles 
 
Significant efforts have been devoted over the past forty years to the fabrication of GoldNP with 
monodispersity and controlled size, for these experiments they were produced by citrate 
reduction as the Turkevitch method [68]. This process gives uniform and fairly spherical 
particles.  
GoldNPs are the most stable metal nanoparticles. Nanoscale particles of gold now command a 
great deal of attention for biomedical applications. Depending on their size, shape, degree of 
aggregation, and local environment, gold nanoparticles can appear red, blue, or other colors. 
These visible colors reflect the underlying coherent oscillations of conduction-band electrons 
[69]. 
Metal nanoparticles such as gold are excellent candidates for bioconjugation with biological 
molecules. Many researchers have shown that biologically active substances with amine 
functions can bind strongly with gold nanoparticles [70].  
The tunable shape and size dependent optical properties of gold nanoparticles have been 
exploited in various surface coatings and biomedical applications. They are biocompatible, 
nontoxic, bind readily to a large range of biomolecules such as amino acids, proteins/enzymes 
and DNA and expose large surface areas for immobilization of such biomolecules [71,72].  
 
Figure 6. A schematic illustration of drug delivery via ‘active’ and ‘passive’ targeting. GNP indicates 
polysaccharide-matrix nanoparticle with GoldNP [73] 
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The ability to modulate the surface chemistry of gold nanoparticles by binding suitable ligands 
has important applications in many areas such as drug and DNA delivery, as well as, novel 
organic reactions and sensors (both inorganic and biological entities) [72].  
Drug delivery systems (DDS) provide positive attributes to a free drug by improving solubility, 
in vivo stability, and biodistribution. They can also alter unfavorable pharmacokinetics of some 
free drugs. Moreover, huge loading of pharmaceuticals on DDSs can render drug reservoirs for 
controlled and sustained release to maintain the drug level within therapeutic window [73].  
Gold nanoparticles are capable of delivering large biomolecules, without restricting themselves 
as carriers of only small molecular drugs. Tunable size and functionality make them a useful 
scaffold for efficient recognition and delivery of biomolecules, peptides, proteins, or nucleic 
acids like DNA or RNA [73]. 
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3. Materials and Methods 
 
3.1. Materials 
 
Medium molecular weight chistosan (MMWC) (248 kDa, DD 93%, apparent viscosity 150 cps) 
was purchased from Altakitin (Portugal). Bortezomib (Velcade) and Calcitriol (Rocaltrol) were 
purchased from Selleck Chemicals LLC (USA). dimethyl sulfoxide (DMSO) was from 
SigmaChemical Co. Gum arabic 51201 (MW 250 kDa), polysorbate 80, glacial acetic acid 
>99.7% (MW 60.05), sodium hydroxide, phosphate buffered saline (PBS) were purchased from 
Sigma-Aldrich (Germany).  Catechins Sunphenon EGCG (458 Da) was purchased from Taiyo 
Kaguku (Japan).   
All aqueous solutions were prepared in ultrapure Milli-Q water (Milli-Q Academic, Millipore, 
France). 
  
3.2. Preparation of Nanoparticles 
 
The suitable masses of chitosan were dissolved in 1% (v/v) acetic acid aqueous solution to 
attain the desire final concentrations and the pH of the chitosan solutions adjusted to 4.5-5 with 
10% sodium hydroxide aqueous solution. GA solutions were prepared in ultrapure Milli-Q 
water. 
The preparation of the nanoparticles for characterization was performed by dropwise addition of 
GA into the chistosan solutions, volume proportion of 1:1 CS/GA nanoparticles (final volume 
5.0 mL), followed by magnetic stirring at 250 rpm for 15 min at room temperature. 
The CS/GA concentration ratios tested were 0.75, 1 and 1.5 with a CS concentration of 0.075, 
0.3, 0.6 mg·mL
-1
. 
 
Bortezomib/Gold NP – loaded nanoparticles 
For the bortezomib and polymer nanoparticles, the entrapment procedure was followed by 
adding the bortezomib to the GA solution, and depending on the case,  immediately or before 
followed by magnetic stirring at 250 rpm for 15 min at room temperature, added dropwise to 
chitosan solution following the same procedure as for the unloaded nanoparticles preparation. 
The chosen ratios were of 0.75 with a CS concentration of 0.3 mg·mL
-1
 for the CS/GA system, 
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it means, CS 0.03% (w/v) and GA 0.04%(w/v). The bortezomib was added from a stock 
solution of 1 mg/mL in DMSO to have 10% (w/w) from the unloaded nanoparticles.  
In case of bortezomib/GoldNP-loaded nanoparticles, the entrapment procedure was followed by 
adding the bortezomib and GoldNP to the GA solution by magnetic stirring at 250 rpm for 15 
min at room temperature, and following added dropwise to chitosan solution following the same 
procedure as for the unloaded nanoparticles preparation. The chosen ratios were of 0.75 with a 
CS concentration of 0.075 mg·mL
-1
 for the CS/GA system, it means, CS 0.075% (w/v) and GA 
0.01%(w/v). The bortezomib was added from a stock solution of 1 mg/mL in DMSO to have 
10% (w/w) from the unloaded nanoparticles. The GoldNP solution was added in order to have a 
final concentration of 0.9 nM.  
Finally, for the GoldNP-loaded nanoparticles, the entrapment procedure was followed by adding 
GoldNP to the GA solution immediately, followed by adding dropwise to chitosan solution 
following the same procedure as for the unloaded nanoparticles preparation. The chosen ratios 
were of 0.75 with a CS concentration of 0.3 mg·mL
-1
 for the CS/GA system, it means, CS 
0.03% (w/v) and GA 0.04%(w/v). The GoldNP solution was added in order to have a final 
concentration of 0.9 nM.  
The coating of the particles' surface with polysorbate 80 was carried out by adding it at the end 
of last 15 minutes reaction, testing concentration of 1% (v/v). 
 
EGCG/GoldNP-loaded nanoparticles 
For the EGCG/GoldNP-loaded nanoparticles, the entrapment procedure was followed by adding 
the EGCG and GoldNP to the GA solution, and depending on the case,  immediately or before 
followed by magnetic stirring at 250 rpm for 15 min at room temperature, added dropwise to 
chitosan solution following the same procedure as for the unloaded nanoparticles preparation. 
The chosen ratios were of 0.75 with a CS concentration of 0.075 mg·mL
-1
 for the CS/GA 
system, it means, CS 0.075% (w/v) and GA 0.01%(w/v).The EGCG was added from a stock 
solution to have 10% (w/w) from the unloaded nanoparticles. The GoldNP solution was added 
in order to have a molar proportion 1:500 GoldNP/GA that means a final concentration of 2.25 
nM. 
The coating of the particles' surface with polysorbate 80 was carried out by adding it at the end 
of last 15 minutes reaction, testing concentration of 1% (v/v). 
 
Vitamin D/GoldNP -loaded nanoparticles 
In case of Vitamin D/GoldNP-loaded nanoparticles, the entrapment procedure was followed by 
adding the vitamin D and GoldNP to the GA solution and immediately added dropwise to 
chitosan solution following the same procedure as for the unloaded nanoparticles preparation. 
The chosen ratios were of 0.75 with a CS concentration of 0.075 mg·mL
-1
 for the CS/GA 
system, it means, CS 0.075% (w/v) and GA 0.01%(w/v). The vitamin D was added from a stock 
solution of 1mg/mL in DMSO to have 10% (w/w) from the unloaded nanoparticles. The 
GoldNP solution was added in order to have a final concentration of 0.9 nM. 
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The coating of the particles' surface with polysorbate 80 was carried out by adding it at the end 
of last 15 minutes reaction, testing concentration of 1% (v/v). 
 
The preparation of the nanoparticles was run under a laminar flow chamber and all experiments 
were performed by triplicate.  
 
3.2. Preparation of Gold Nanoparticles 
 
Citrate-coated GoldNP were prepared by citrate reduction of HAuCl4. 125 mL Ultrapure Milli-
Q was heated until boiling point followed by addition of 86 μL HAuCl4 dropwise, stirling at 500 
rpm. Aqueous solution of sodium citrate was prepared (12.5 mL, 11 mg/mL) and afterwards 
added into preparation. It was kept covered until preparation turned black colored. Then, 
temperature was decreased and kept it covered during 4 min. Following, preparation was 
uncovered and without heating but maintained stirling 3 min.   
 
 
3.3. Physicochemical characterization 
 
The size, polydispersity index, zeta potential and morphological appearance were the 
parameters used to characterize the produced nanoparticles.  
 
3.3.1. Particle size 
 
Dynamic light scattering (DLS) is the mainly technique used to determine molecules and 
particles size (hydrodynamic diameter) and size distribution of nanoparticles in dispersion or 
solution. Shining a monochromatic light beam, such as laser, onto a solution with particles in 
Brownian motion, causes a Doppler Shift when the light hits the moving particle, changing the 
wavelength of the incoming light. This change of the wavelength is measured by the intensity of 
the scattered light in that microsecond time range and permit determine the particles size 
distribution. 
For spherical monodisperse particles, the hydrodynamic diameter, dp, can be determined from 
the diffusion coefficient, D, which is characteristic of the Brownian motion, using the Stokes-
Einstein relation (Eq. 1) 
  
   
     
                                                                       (1) 
where kB is the Boltzmann constant, T the absolute temperature and η the viscosity. 
 Polysaccharide-gold nanoparticles as anticancer drugs carriers.  
- 19 - 
 
Measurements of particle size and polydispersity index were performed by a ZetaSizer Nano ZS 
(Malvern Instruments, Worcestershire, UK), using a clear disposable zeta cell at approximately 
25ºC and an angle of the laser incidence of 173º. Mean values for each preparation were 
obtained by at least duplicate measurements of three different batches.  
 
3.3.2. Zeta potential 
 
The zeta potential is generally determined by electrophoretic mobility, calculated by Henry 
equation (Eq. 2). It is used in order to characterize their surface properties and stability in 
suspensions. Performing an electrophoresis experiment by applying an electric field across the 
sample, measuring the velocity of the particles due to the tendency to oppose this movement. 
After the equilibrium between them is attained, the particles move at a constant velocity, which 
is known as electrophoretic mobility (UE). 
   
        
  
                                                               (2) 
where ε is the dielectric constant, ξ the zeta potential, η the viscosity and f(ka) the Henry's 
function, which for aqueous medium and moderate electrolyte concentration is considered 1.5. 
In that case, the zeta potential can be determined from the electrophoretic mobility measured by 
the Smoluchowski equation (Eq. 3). 
  
   
 
                                                                    (3) 
The zeta potential gives an indication of the potential stability of the system. The system is 
considered stable when the particles in suspension have a large negative or positive zeta 
potential. Due to their tendency to repel each other and avoid to flocculate or to aggregate. If the 
value is between -30 and 30 mV, the system is considered unstable because there is no force 
enough to prevent aggregation of particles. 
The zeta potential was also measured using a ZetaSizer Nano ZS (Malvern Instruments, 
Worcestershire, UK), making use of Laser Doppler Velocimetry. All the determinations were 
performed in a clear disposable zeta cell at approximately 25ºC and a light scattered at an angle 
of 17º. Mean values for each preparation were also obtained by at least duplicate measurements 
of three different batches.  
 
3.3.3. Morphologic analysis 
 
Transmission Electron Microscopy (TEM) is an electron microscopy technique that produces an 
image that is a projection of the entire object including the surface and the internal structures 
enabling the characterization of the structure geometry.  
The transmission electron microscope (TEM) operates on the same basic principles as the light 
microscope but uses electron beam instead of light to interact with the sample. Being the 
intensity influenced by its thickness and by the concentration of atoms of that sample.  
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It requires being thin or it will absorb in excess the electron beam. All the waves in the incident 
beam are in phase with each other because the electrons come from a single source. 
The samples are typically put on support grids made of Cu, that possess an ultramicrotomy 
mesh. Samples of biological origin are generally negatively stained by uranyl acetate or 
phosphotungstic acid.  
In this work, a sample of 10 μL of each prepared solution was placed over a carbon coated 
copper TEM grid (Formvar/Carbon on 400 mesh Cu (50) from Agar Scientific), and stained 
with a 2% (v/v) phosphotungstic acid solution. The images were observed on a TEM Yeol Yem 
1400 (80 kV) (Tokyo, Japan) with a Digital Camera Orious 1100 (Japan).  
 
 
3.4. Loading efficiency  
 
To determine the drug-loading efficiency each suspension was centrifuged at 14,000 rpm for 30 
minutes using MiniSpin Plus (Eppendorf) centrifuge to remove the extra GA and 
unencapsulated drug. The absorbance of the supernatant was measured to indirectly calculate 
the encapsulation efficiency for all the preparations, also taking into account the almost 
insignificant quantity of escaped drug after three times washing the pellets with ultrapure water.  
UV-vis spectra of each drug in the range of 200-700 nm was analyzed by using a UV-1700 
PharmaSpec UV-Vis spectrophotometer from Shimadzu (Japan), using HOQ 310H quartz cells 
(Hellma) of 1 cm path length.  
The concentration of each drug in solution was determined by the peak area from the 
absorbance UV-Vis signal correlated with the respective calibration curve of the drug in water 
that was prepared under identical conditions. In case of Bortezomib the calibration curve was 
between 5 and 300 μM, for EGCG was between 5 and 100 μM, and finally, for vitamin D was 
between 10 and 100 μM. 
The encapsulation efficiency (%) is calculated by the Eq. 4.  
 
                             
                      
                           
                    (4) 
 
The drug capacity is defined by the percentage of mass of drug in the mass of nanoparticles 
material.  
In order to determine the samples those contain also Gold NPs, it was analyzed the peak of the 
sample around 522-527 nm using the Lambert-Beer Law (Eq. 5).  
The Lambert-Beer Law states that the optical absorbance of a chromophore, as gold, in a 
transparent solvent varies linearly with both the sample cell pathlength and the chromophore 
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concentration. Beer's Law is the simple solution to the more general description of Maxwell's 
far-field equations describing the interaction of light with matter. [74] 
                                                                       (5) 
Where A is the absorbance on the characteristic wavelength, ε molar absorptivity or extinction 
coefficient of the chromophore at wavelength characteristic of each material, l sample 
pathlength in centimeters and C concentration of the compound in the sample, in molarity. In 
case of gold, values for molar absorptivity, ε, is 2.33·108 and sample pathlength, l, 1 cm.  
 
 
3.5. Bortezomib release from particles 
 
Drug release experiments of the chitosan and gum arabic nanoparticles were run using a dialysis 
bag. The realease studies were made with sample of  bortezomib/GoldNP-loaded nanoparticles. 
The dialysis bags used in these cases were the Float-A-Lyzer of 2 mL and a 100 kDa molecular 
weight cut off (MWCO) with Biotech Grade Cellulose Ester (CE) Membranes from Spectrum 
Labs.  
Before starting the experiments the membranes were washed in ultrapure water for 12 hours and 
with Phosphate Buffered Saline (PBS) 1 hour before the beginning of the experiment run with 
PBS as the receiving phase. 1 mL of the nanoparticles aqueous suspension were added into the 
membrane and the outside space was filled with 5 mL of water or PBS at pH 7.4, in a way to 
mimic the physiological medium where the particles are being released when administered. It 
was continuously stirred at 250 rpm at room temperature. 1 mL sample was taken from the 
inside medium at different time intervals to obtain the UV-vis spectra in the range of 200-700 
nm, using the same spectrophotomer, and then returned.  
This way, it turned possible to determine the bortezomib concentration that had passed the 
membrane at each time by correlating the peak area from the absorbance signal and the 
bortezomib calibration curve in water or PBS, depending on each case. The concentration 
determined in each time (Ct) was compared with the once of the sample at time zero (C0).  The 
bortezomib released percentage at each time is then calculated from the Equation 6. This 
method was used to guarantee that bortezomib concentration was always able to be measure by 
UV. 
                                   
            
         
                              (6) 
 
The release of bortezomib at same conditions and concentration was used as control. 
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3.6. Cytotoxicity studies 
 
Chemicals 
Bortezomib (Velcade) was purchased from Selleck Chemicals LLC (USA); Fetal bovine serum 
(FBS), phosphate buffered saline (PBS), trypsin and Dulbecco's Modified Eagle (DMEM) 
medium were from Gibco Invitrogen Co. (Scotland, UK). Acetic acid, dimethyl sulfoxide 
(DMSO), sulforhodamine B (SRB) and trypan blue were from SigmaChemical Co. 
Tricloroacetic acid (TCA) and Tris were sourced from Merck (Darmstadt, Germany).   
A BTZ stock solution was prepared in DMSO at room temperature to obtain the final BTZ 
concentration of 1 mg/mL. 
 
Cell line culture 
The human pancreatic cancer cell line S2-013 and the human normal pancreatic cells HPNE 
were provided by Prof. M. A. Hollingsworth (UNMC – Omaha, USA) and were cultured in the 
DMEM medium, supplemented with 10% FBS. The cell cultures were maintained at 37ºC in 
humidified atmosphere with 5% CO2.  
 
Cell viability assay 
The experiments were performed with human pancreatic cells, the S2-013 and the HPNE. The 
cells were seeded in 96-well plates at a density of 1x10
4
 cell/mL for an incubation period of 24 
h. The samples Ch/GA, Ch/GA/PEGAuNPs, BTZ loaded Ch/GA (Ch(GA-BTZ)) nanoparticles 
and BTZ free were diluted in DMEM medium and the final concentrations ranging between 
0.001 and 200nM. The cells were incubated for 48 h with different sample concentrations. The 
control group was cultivated in the corresponding growth medium without samples and all 
samples were tested in triplicates. Cell viability was determined using the PrestoBlue (PB) and 
sulforhodamine B (SRB) assays. 
PrestoBlue assay measure the cell viability by using the reducing power of living cells to 
quantitatively measure the proliferation of cells. The PrestoBlue reagent is added to cells and is 
modified by the reducing environment of the viable cell, turns red in color and becomes highly 
fluorescent.  For PB assay, 50 µL of PB reagent, diluted 1:10 in DMEM, was incubated in each 
well for 45 minutes, at 37ºC in humidified atmosphere with 5% CO2, followed by the 
fluorescence reading (excitation at 560 nm and emission at 590 nm) using a microplate reader 
(PowerWave HT Microplate Spectrophotometer, BioTek).  
SRB assay is used for cell density determination, based on the quantification of cellular protein 
content. The cells were fixed in situ with 50 µL of PBS and 25 µL of TCA for 1 h, in 
refrigerator. After the incubation period, cell monolayers were washed and stained with 50 µL 
of SRB dye for 30 minutes. After washed repeatedly with 1% (vol/vol) of acetic acid to remove 
the excess dye and dried, the protein-bound dye is dissolved in 10 mM Tris base solution for 
absorbance determination at 560 nm using a microplate reader (PowerWave HT Microplate 
Spectrophotometer, BioTek). 
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Concentration-response curves using non-linear regression analysis were obtained and the 
concentration inhibing cell survival by 50% (IC50) as well as, the concentration inhibiting the 
net cell growth by 50% (GI50) were determined. IC50 and GI50 are the concentrations of test drug 
where Equations 7 and 8, respectively, are applicable.  
 
 
 
                                                                       (7) 
 
      
      
                                                                    (8) 
 
where T is the quantitative measurement at the end of the incubation period, T0 is the 
quantitative measurement at the time of test drug addition and C is the quantitative 
measurement in the control wells. 
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4. CS/GA system 
 
4.1. Unloaded CS/GA nanoparticles 
 
In order to set the most favorable formulations for the nanoparticles, different CS/GA 
concentration ratios were tested varying, as well, chitosan and gum Arabic ratios.  
Polyelectrolyte complexation of chitosan and gum arabic made possible the formation of 
nanoparticles. They were produced by the dropwise addition of negatively charged GA into the 
positively charged chitosan solution.  An alteration of the solution from clear to opalescent was 
noticed, which indicates a change on the chitosan physical state to form nanoparticles. 
 
4.1.1. Size and zeta potential characterization 
 
The results of the mean diameter (dm), polydispersity index and zeta potential of the produced 
nanoparticles are presented in Table 1. 
 
Table 1. Physicochemical characterization of CS/GA nanoparticles. Data represented as mean ± SD. 
Ratio CS/GA CCS [mg/mL] CGA [mg/mL] dm [nm] PdI [-] ZP [mV] 
0.75 0.075 0.1 259 ± 5 0.2 ± 0.0 46 ± 1 
0.75 0.3 0.4 374 ± 4 0.3 ± 0.2 49 ± 2 
1.00 0.3 0.3 325 ± 3 0.3 ± 0.1 51 ± 1 
1.50 0.3 0.2 319 ± 5 0.3 ± 0.1 52 ± 1 
0.75 0.6 0.8 397 ± 2 0.3 ± 0.1 49 ± 2 
1.00 0.6 0.6 341 ± 4 0.3 ± 0.3 52 ± 1 
1.50 0.6 0.4 351 ± 4 0.3 ± 0.2 52 ± 1 
 
Overall, the method followed for the preparation of CS/GA nanoparticles produced well-
stabilized monodisperse nanoparticles. NPs present a size between 260-400 nm, uniformly 
distributed, PdI around 0.3 and zeta potential varying from 46 to 52 mV.  
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As it well known, CS/GA nanoparticles were formed due to the interaction of the functional 
groups of both macromolecules (-NH
3+
 and -COO
−
), [75] [76]. Due to this interaction, size 
possibly increases when GA concentration was higher because of more amine groups from 
chitosan became neutralized, which decreased the positive charged surface and favored the 
attraction between both components, resulting in larger mean diameters due to more 
polysaccharade molecules interact in the union.  
Observing the results of different formulations, sizes generally increased as the gum Arabic 
concentration increased, particularly, making visible the tendency explained before. Even so, 
zeta potential did not vary significantly, being all the nanoparticles positively charged. The 
responsibility of this fact, could be related to the residual amine groups.  
This effect may be related to the absorption of anionic groups by the long amino groups of 
chitosan to keep the high value of the electrical double layer thickness, which in turn prevents 
the aggregation [77]. 
When formulations with the same CS/GA ratios are compared, it is possible to appreciate that 
with higher concentration of CS, main characteristics, mean diameter and zeta potential, slightly 
increased. However it is not possible to compare directly all results because of the fact that GA 
concentrations were different for each case of chitosan concentration tested.  
The selected conditions for the drug-loading nanoparticles were the ratio 0.75. As it was shown 
in the experiments, for nanoparticles with just drug it was used as CS concentration of 0.3 
mg/mL but in the case of  the drug plus GoldNP, the CS concentration was 0.075 mg/mL.  
These selected concentrations were chosen because of their appropriate size and high zeta 
potential, which indicates that they were stable. Additionally, it presents low polydispersity. In 
the case of added GoldNP, the same ratio but lower concentrations were selected to avoid the 
excess of non reacted material.  
 
4.1.2. Morphologic analysis 
 
The analysis of nanoparticles morphology was performed by TEM. The images of the unloaded 
CS/GA nanoparticles of one of the chosen formulation are shown in Figure 7. This formulation 
corresponds to CS/GA ratio of 0.75 with CS concentration of 0.3 mg/mL. 
Figure 7. TEM micrographic pictures of free CS/GA nanoparticles. The scale bar corresponds to 400 nm. 
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Figure 7 shows a relatively spherical shape with a dense structure from the free CS/GA 
nanoparticles. TEM images expose that the diameter of the nanoparticles varies slightly between 
250 and 400 nm, but still confirms the size determinate by DLS.  
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4.2. Bortezomib/Gold NP-loaded CS/GA nanoparticles 
 
4.2.1. Size, zeta potential and encapsulation efficiency 
 
The size, polydispersity index and zeta potential values for the bortezomib-entrapped CS/GA 
NPs are presented in Table 2, as well as the different conditions of time and preparation. The 
bortezomib and GoldNP encapsulation efficiencies and loading capacities are presented in Table 
3.  
 
Table 2.  Physicochemical characterization for uncoated and coated by polysorbate80 nanoparticles with 
different conventions of BTZ and GoldNP. Data represented as mean ± SD. 
Drug-loaded [-] Time [min] Cp80 [% v/v] dm [nm] PdI [-] ZP [mV] 
BTZ 0 0 258 ± 7 0.2 ± 0.02 48 ± 2 
BTZ 15 0 289 ± 9 0.3 ± 0.03 47 ± 3 
AuNP 0 0 316 ± 5 0.2 ± 0.01 50 ± 1 
AuNP (PEG) 0 0 306 ± 6 0.2 ± 0.01 51 ± 1 
BTZ+AuNP(PEG) 15 0 355 ± 8 0.3 ± 0.08 38 ± 4 
BTZ+AuNP(PEG) 15 1.0 478 ± 12 0.4 ± 0.04 46 ± 2 
 
 
Table 3. Bortezomib and GoldNP encapsulation efficiency and loading capacity with different 
combination of BTZ and GoldNP – CS/GA nanoparticles. Data represents mean ± SD.  
 
  
BTZ AuNP  
Drug-loaded 
[-] 
Time 
[min] 
Cp80 
[% v/v] 
En.Eff. [%] Load. C. [%] En.Eff. [%] Load. C. [%] 
BTZ 0 0 45 ± 4 4.1 ± 1.2 - - 
BTZ 15 0 58 ± 5 4.7 ± 2.6 - - 
AuNP 0 0 - - 100 ± 0 4.1·10
-6
 ± 0.0·10
-6 
AuNP (PEG) 0 0 - - 100 ± 0 4.1·10
-6
 ± 0.0·10
-6 
BTZ+AuNP(PEG) 15 0 65 ± 3 0.2 ± 0.02 94 ± 3 1.4·10
-6
 ± 0.2·10
-6 
BTZ+AuNP(PEG) 15 1.0 77 ± 9 0.3 ± 0.03 95 ± 2 1.3·10
-6
 ± 0.1·10
-6 
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The electrostatic interactions between the positively charged group of chitosan and negatively 
charged groups of GA plays an important role in the association efficiency of the added drug in 
nanoparticles [77], thus, when the bortezomib is entrapped, the size of BTZ-CS/GA decreased 
when compare to the unloaded ones. The zeta potential of loaded and unloaded nanoparticles do 
not change significantly. 
Focusing in encapsulation, modifying method of preparation leaving BTZ 15 minutes in 
magnetic stirring with GA has shown that encapsulation efficiency increases significantly. This 
observation can be explained by the time effect on the BTZ entrapping process.    
In the case of addition of GoldNP, unpegylated and pegylated, and BTZ-GoldNP-CS/GA 
nanoparticles the opposite behavior was observed. In all cases, the mean diameter increased in 
respect to the unloaded ones. However, the zeta potential does not vary significantly compared 
to the CS/GA nanoparticles in each case of CS concentration. 
 In both cases, as it was analyzed after centrifugation process with colorless solution, all 
GoldNP present in preparation became entrapped between CS/GA matrix. Due to the similarity 
of physicochemical characteristics and encapsulation efficiency between GoldNP and pegylated 
GoldNP CS/GA nanoparticles, the next experiments were performed with pegylated GoldNP. It 
was chosen because of side benefits of pegylated particles, since the strong steric stabilization 
property of the PEG layer lends the nanoparticles high dispersion stability [78] and has 
remarkable stability under physiological conditions [79]. 
The coating of the nanoparticles surface with polysorbate 80 was also studied, just with 1% v/v 
to have a preliminary vision of its effect on the nanoparticle characteristics. It was only tested in 
BTZ and GoldNP- CS/GA nanoparticles.  
For CS/GA nanoparticles with BTZ and GoldNP(PEG), both coated and uncoated particles, it 
was noticed higher sizes compared to the unloaded ones. Gold encapsulation efficiency is 
similar in both cases and does not vary significantly between GoldNP-CS/GA nanoparticles.  
However, zeta potential and BTZ encapsulation depend on the coating of nanoparticle’s surface. 
Uncoated nanoparticles presented a lower zeta potential, therefore, lower stability. On the other 
hand, coated nanoparticles maintained a zeta potential similar to the CS/GA nanoparticles. 
There is not a significant alteration on the zeta potential of coated nanoparticles because it is a 
nonionic tensioactive, which could be not only on the surface but also inside the nanoparticles 
matrix [78].   
Encapsulation efficiency increases in the case of coated nanoparticles probably due to the effect 
surface stabilization by polysorbate80. A significant increase of the mean diameter of coated 
nanoparticles was observed.   
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4.2.2. Morphologic analysis 
 
TEM photographs of the bortezomib-loaded CS/GA nanoparticles and bortezomib/GoldNP-
loaded CS/GA nanoparticles are shown in Figure 8. The effect of polysorbate 80 on the 
nanoparticle morphology was also investigated. 
 
Figure 8. TEM micrographs of BTZ-CS/GA nanoparticles (right) and BTZ and GoldNP-CS/GA-p80 
nanoparticles (left). The scale bar corresponds to 200 nm. 
 
Generally, TEM images showed for the different combinations of BTZ and GoldNP-loaded 
nanoparticles a spherical shape and relatively monodisperse nanoparticles. Comparing both 
images, it is possible to determinate that polysorbate stabilizes the nanoparticle surface 
providing a more well defined spherical shape.  
Despite this, on the right image (Figure 8), it is possible to appreciate an excess of polysorbate 
on the surface of the nanoparticles, which causes an increase of mean diameter of the particles, 
thus, explaining the differences in the DLS measures between coated and uncoated 
nanoparticles.  
The right image of Figure 8, also proves that GoldNP are inside and/or on the particle surface, 
which confirms the results of the encapsulation efficiency. 
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4.2.3. Bortezomib release from the nanoparticles 
 
The dialysis studies were performed in order to identify the release profile of bortezomib when 
it is free and loaded as BTZ-GoldNP-CS/GA nanoparticles. The experiments were carried out in 
sterilized ultrapure water (Figure 9) and in phosphate buffered saline (Figure 10). Both 
experiments were performed at room temperature (25ºC).  
 
 
 
 
 
 
 
 
 
Figure 9. Studies of bortezomib difusion in water at 25ºC, free and entrapped in CS/GA NP. 
 
 
 
 
 
 
 
 
 
Figure 10. Studies of bortezomib diffusion in PBS at pH 7.4. at 25ºC free and entrapped in CS/GA NP. 
 
These preliminary release experiments provide guidance in order to predict the profile of the 
drug delivery in the cells. In both receiving phases, bortezomib loaded particles showed a 
variable pattern with a rapid stretch followed by a slower one.  
The initial curve probably corresponds to the free bortezomib that was not encapsulated or the 
one on the surface of NP being easily released. Followed by a more gradual release, which may 
correspond to bortezomib entrapped inside the core of NP. Throughout the dialysis studies it 
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was also controlled the release of GoldNP, which it was null or impossible to detect over the 
time that the experiments were performed.  
By comparing both receiving phases, the rapid release was especially visible in the case of PBS, 
where 100% of BTZ was attained after 7 hours compared to 50% of released BTZ after 9 hours 
in ultrapure water. Likewise, the diffusion of free bortezomib was slower in the case of water as 
receiving medium (OUT). 
As it is shown in Figure 9, encapsulated bortezomib released more than 50% during the first 10 
hours and in the next 40 hours its concentration only increased to approximately 60%. Other 
measurements were taken up to 100h, but the results were similar, which means it entered in a 
stable zone. The free bortezomib showed a more regular curve and was almost completely 
released after 30 hours. The release profile of bortezomib in nanoparticles compared to free 
BTZ was significantly different. 
On the other hand, Figure 10 showed a different profile of bortezomib. The bortezomib release 
started fast as the previous one in water, but between 4-5 hours of release its behavior changed 
and attained values higher than the BTZ free. After roughly 7 hours, all the bortezomib in 
nanoparticles was released. Furthermore, this change was externally appreciated with the loss of 
characteristic coloration of GoldNP.  
In order to inquire that, it was measure the size and ZP of the nanoparticles after 7 hours of 
release. The results are shown in Table 4, which show how nanoparticles are modified and 
unstable after 7 hours. Based on these results, it is possible to appreciate that nanoparticles 
started to degrade after 4-5 hours of being in PBS, which permitted to conclude that 
nanoparticles are biodegradable in PBS. 
  
Table 4.  Physicochemical characterization for BTZ and GoldNP CS/GA nanoparticles before and after 
7h of release in PBS receiving phase. Data represented as mean ± SD. 
Time of release [h] dm [nm] PdI [-] ZP [mV] 
0 355 ± 8 0.3 ± 0.08 38 ± 4 
7 1.1·10
4
 ± 2.8·104 1.0 ± 0.0 -8.5 ± 0.6 
 
In general, as it has been reported, the size, solubility, composition, density and biodegradation 
of the nanoparticle matrix are the main factors that affect the release rate of a drug from 
nanoparticles [80]. Furthermore, in the majority of cases, drug release follows more than one 
type of transport mechanism [81].  
In the case of release from the surface, adsorbed drug instantaneously dissolves when it comes 
in contact with the release medium. Drug entrapped in the surface layer of particles also follows 
this mechanism. This type of drug release leads to burst effect, as it was observed with 
bortezomib loaded in CS/GA system.  
Then it follows the diffusion of BTZ whose release kinetics are described by Fick's second law 
of diffusion [82]. Drug release by diffusion involves three steps. First, water penetrates into 
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particulate system, which causes swelling of the matrix; secondly, the conversion of glassy 
polymer into rubbery matrix takes place, while the third step is the diffusion of drug from the 
swollen rubbery matrix. Hence, the release is slow initially and later it becomes fast. Release by 
diffusion depends on the particle size [81].  
Other possible transport mechanism is analyzed by Higuchi equation [83]. Originally, Higuchi 
equation was used to describe the release of a solute from a flat surface, not from a sphere, but 
modified equation for spherical systems obtained a good results in different studies [84], which 
suggests that the release rate depends upon the rate of diffusion through the cross-linked matrix 
[81]. When the matrix is not homogenous but instead contains granular materials, the release of 
solid drug involves the simultaneous penetration of the surrounding liquid, the dissolution of 
drug, and leaching out of the drug solution through the pores [82].  
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4.2.4. Cytotoxicity studies 
 
In vitro cytotoxicity studies were performed on a human pancreatic cancer cell (S2-013) and on 
human normal pancreatic cells (HPNE). GoldNP(PEG) CS/GA and BTZ CS/GA nanoparticles 
were tested in both cell lines and compared to free bortezomib using PB and SRB assays. 
Different concentrations of GoldNP(PEG) CS/GA nanoparticles and bare CS/GA nanoparticles 
have shown in general no deleterious effect on cell viability in both lines of human pancreatic 
cells. Results by PB method are presented in Figure 11, and by SRB method in Figure 12, 
related with Table 5. Polysorbate 80 was also tested in order to check its cytotoxicity, which it 
was appreciated specially  in cancer cells (Figure 11 and Figure 12, left, number 1 and 2). Due 
to the possible cytotoxicity effects of Polysorbate 80, the next studies were carried out with 
uncoated nanoparticles to overcome misunderstanding of the cell response to the nanoparticle 
toxicity. In Figure 12 (left graph) it is observed that GoldNP CS/GA NP and CS/GA coated, in 
highest concentrations, may have a cytotoxic effect, however it was just shown in cancer cells 
and by SRB assay.  
 
 
 
 
 
 
 
Figure 11. Cell survival after 48h exposure to GoldNP (PEG) CS/GA nanoparticles by PB assay. (left) 
Cancer cell line, S2-013. (right) Normal cell line, HPNE. Numbers refer to Table 5. Number 8 is the 
reference.  
 
 
 
 
 
 
 
 
Figure 12. Cell survival after 48h exposure to GoldNP (PEG) CS/GA nanoparticles by SRB assay. (left) 
Cancer cell line, S2-013. (right) Normal cell line, HPNE. Numbers refer to Table 5. Number 8 is the 
reference.  
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Table 5.  Formulations of CS, GA, GoldNP(PEG) and polysorbate 80, which were tested in PB assay 
showed in Figure 11 and 12.  
Number in graph CCS [mg/mL] CGA [mg/mL] CAuNP(PEG) [mg/mL] p80 [mg/mL] 
1 6.53·10
-4 
8.71·10
-4
 1.96·10
-3
 2.33·10
-3
 
2 - - - 1.16·10
-3
 
3 1.63·10
-4
 2.18·10
-4
 4.90·10
-4
 - 
4 8.16·10
-5
 1.09·10
-4
 2.45·10
-4
 - 
5 3.26·10
-5
 4.35·10
-5
 9.79·10
-5
 - 
6 3.26·10
-6
 4.35·10
-6
 9.78·10
-6
 - 
7 3.26·10
-7
 4.35·10
-7
 9.78·10
-7
 - 
 
The BTZ CS/GA and free BTZ showed a bortezomib concentration-related decrease in cell 
survival and growth after 48h exposure, by PB assay. Figure 13 corresponds to human 
pancreatic cancer cells, S2-013; Figure 14, to normal pancreatic cells, HPNE. 
 
 
 
 
 
normals  
 
Figure 13. Cytotoxic effects of bortezomib free and entrapped in CS/GA NP uncoated on cell line S2-
013, determined by PB assay: (right) effects of BTZ on cell survival and (left) effects on cell growth. 
 
 
 
 
 
 
 
Figure 14. Cytotoxic effects of bortezomib free and entrapped in CS/GA NP uncoated on cell line HPNE, 
determined by PB assay: (right) effects of BTZ on cell survival and (left) effects on cell growth. 
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Generally, it is noticed more deleterious effects by free bortezomib than by BTZ CS/GA 
nanoparticles. By PB method, in pancreatic cancer cells with lower concentration of BTZ 
encapsulated in CS/GA nanoparticles the same % of survival cells is achieved as with higher 
concentration of free BTZ (Figure 13, left), what is confirmed by results of death cells (Figure 
13, right).  
On the other hand, in normal pancreatic cells, for the highest concentrations, more cells survive 
in the presence of BTZ CS/GA nanoparticles than of free bortezomib at the same concentration 
(Figure 14, left). Furthermore, at these highest concentrations, while free bortezomib produced 
the death of normal cells, BTZ CS/GA nanoparticles just inhibited their growth (Figure 14, 
right).  
In order to complete these results, the BTZ CS/GA and free BTZ were also tested by SRB 
assay, checking as well the cell survival and growth after 48h exposure. Figure 15 corresponds 
to human pancreatic cancer cells, S2-013; Figure 16, to normal pancreatic cells, HPNE. 
 
 
 
 
 
 
 
 
 
Figure 15. Cytotoxic effects of bortezomib free and entrapped in CS/GA NP uncoated on cell line S2-
013, determined by SRB assay: (right) effects of BTZ on cell survival and (left) effects on cell growth. 
 
 
 
 
 
 
 
 
Figure 16. Cytotoxic effects of bortezomib free and entrapped in CS/GA NP uncoated on cell line HPNE, 
determined by SRB assay: (right) effects of BTZ on cell survival and (left) effects on cell growth. 
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Comparing these results with PB assay, less aggressive character of BTZ CS/GA NPs was 
analyzed with pancreatic cancer cells as Figure 15 shows. BTZ encapsulated and free had more 
similar behavior as % of survival cancer cells, however encapsulated BTZ inhibited the growth 
but did not cause cell death. The same behavior was observed in the response of pancreatic 
normal cells (Figure 16).   
Table 6 and Table 7 present the results of concentration inhibing cell survival by 50% (IC50) and 
the concentration inhibiting the net cell growth by 50% (GI50) for BTZ entrapped and free 
obtained by each method, as well as for each cell line.   
 
Table 6.  Cytotoxic effects of bortezomib on the survival and growth of a human pancreatic cancer cell 
line and a human pancreatic normal cell line. Results are expressed as IC50 at 48 h of exposure with 
respective 95% conficence limits for bortezomib free and encapsulated and by PB and SRB assay. 
 
 
Free BTZ BTZ loaded CS/GA NP 
Cell line Method X 
Upper 
limit 
Lower 
limit 
X 
Upper 
limit 
Lower 
limit 
S2-013 PB 0.23 0.85 -0.46 0.23 0.86 -0.49 
HPNE PB 0.77 1.13 0.23 0.61 0.79 0.42 
S2-013 SRB 0.54 1.03 -0.23 0.11 0.50 -0.46 
HPNE SRB -0.19 0.31 -0.63 0.89 1.03 0.75 
 
 
Table 7.  Cytotoxic effects of bortezomib on the survival and growth of a human pancreatic cancer cell 
line and a human pancreatic normal cell line. Results are expressed as GI50 at 48 h of exposure with 
respective 95% conficence limits for bortezomib free and encapsulated and by PB and SRB assay. 
 
 
Free BTZ BTZ loaded CS/GA NP 
Cell line Method X 
Upper 
limit 
Lower 
limit 
X 
Upper 
limit 
Lower 
limit 
S2-013 PB 1.68 7.09 0.35 1.69 7.21 0.32 
HPNE PB 5.93 13.48 1.69 4.02 6.23 2.63 
S2-013 SRB 3.46 10.63 0.59 1.30 3.14 0.35 
HPNE SRB 0.65 2.03 0.23 0.11 0.50 -0.46 
 
These quantitative results show that in pancreatic cancer cells BTZ CS/GA nanoparticles are 
more effective at decreasing cell survival and inhibiting cell growth, as it presents the lowest 
IC50 and GI50 values. Even so, the major differences are obtained by SRB method.  
The IC50 and GI50 values attained by PB assay in cancer cell line as well as in normal cell line 
are not significantly different for free bortezomib or bortezomib loaded in CS/GA nanoparticles.  
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On the other, by SRB method, entrapped and free bortezomib had different behavior. The IC50  
values noted that lower concentration of bortezomib entrapped is needed at decreasing cell 
survival in cancer cells, but higher concentration is required with normal cells, comparing 
respectively with free bortezomib.  
In addition, results of GI50 agreed with IC50 results, thus, lower concentration of bortezomib 
encapsulated in CS/GA NPs is required to inhibit growth for pancreatic cancer cells, by contrast 
of larger concentration of entrapped bortezomib is needed for inhibit growth of normal cells.  
Although these results are concordant, further studies must be carried out to analyze and 
elucidate the in vitro and in vivo cytotoxicity of the entrapped bortezomib in CS/GA system, 
cell uptake mechanism, intracellular routes, as mucoadhesion and pharmacokinetic 
investigation. As well, it has to be considered results obtained on bortezomib release from 
nanoparticles (Figure 10) which could affect the results. 
Furthermore, the same studies must be performed for BTZ and GoldNP CS/GA nanoparticles, 
to clarify if they have the same effect as the BTZ CS/GA NP and Gold CS/GA NP.  
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4.3. EGCG/GoldNP-loaded CS/GA nanoparticles 
 
4.3.1. Size, zeta potential and encapsulation efficiency 
 
The results of the physicochemical characterization and encapsulation efficiency and loading 
capacity for the EGCG and GoldNP-entrapped CS/GA NPs are presented in Table 8 and Table 
9, respectively. The values characterize the different conditions of time of adding first 
preparation dropwise to chitosan, uncoated and coated nanoparticles were produced. 
 
Table 8.  Physicochemical characterization for uncoated and coated by polysorbate80 nanoparticles with 
different conditions of EGCG and GoldNP. Data represented as mean ± SD. 
Time loaded [min] Cp80 [% v/v] dm [nm] PdI [-] ZP [mV] 
0 0.0 326 ± 5 0.3 ± 0.02 45 ± 2 
15 0.0 334 ± 9 0.3 ± 0.01 50 ± 2 
15 1.0 381 ± 26 0.3 ± 0.02 52 ± 1 
 
 
Table 9. EGCG and GoldNP encapsulation efficiency and loading capacity with different combination of 
EGCG and GoldNP – CS/GA nanoparticles. Data representes mean ± SD.  
  
EGCG AuNP (PEG) 
Time loaded [min] Cp80 [% v/v] En.Eff. [%] Load. C. [%] 
En.Eff. 
[%] 
Load. C. [%] 
0 0.0 37 ± 7 2.8 ± 5.2 95 ± 2 1.2·10-6± 0.1·10-6 
15 0.0 36 ± 3 3.3 ± 1.4 100 ± 0 1.3·10-6± 0.0·10-6 
15 1.0 46 ± 3 4.2 ± 1.9 100 ± 0 1.2·10-6± 0.0·10-6 
 
When the EGCG and the GoldNP were entrapped in CS/GA nanoparticles, the sizes of the 
particles were higher than the free nanoparticles. As well as the zeta potential did, especially, 
how it was expected in case of coated nanoparticles.  
In contrast as bortezomib behavior, in EGCG particles modifying method of preparation 
increasing time for drug and GA preparation did not significantly affect the encapsulation 
efficiency of EGCG.  
This loading capacity may be considered low and may be attributed to the fact that catechins are 
small, highly soluble molecules and their encapsulation is limited through a partitioning 
between the NP space and the surrounding aqueous environment [83], what could explain why 
increasing time is not modifying encapsulation results.   
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Whereas, in case of coating of nanoparticles’ surface by adding polysorbate 80 at the end of 
reaction, it seems it helped to stabilize the nanoparticles by increasing the zeta potential and 
increasing the EGCG encapsulation efficiency roughly 10%. The mean diameter also increased 
but could be explained as TEM images of BTZ and GoldNP-CS/GA-p80 nanoparticles. On 
them, it is appreciated nanoparticles with a thick polysorbate coated which explains the larger 
size.  
Finally relating to GoldNP, as well uncoated as coated, encapsulation was total or nearly 
complete.  
 
4.3.2. Morphologic analysis 
 
TEM micrographs of EGCG and GoldNP CS/GA nanoparticles are presented in Figure 17. In 
both images particles are uncoated.  
Figure 17. TEM micrographs of EGCG and GoldNP-CS/GA uncoated nanoparticles. The scale bar on 
right corresponds to 0.5 µm, and 200 nm on left. 
 
As it was appreciate in bortezomib particles, TEM images clearly revealed spherical 
nanoparticles which are monodisperse and even size.  
On the right image, which is in a lower scale, it is shown that with CS/GA ratio of 0.75 with CS 
concentration of 0.075 mg/mL not only were obtained similar sizes to the free nanoparticles, 
moreover, it was observed that less material non react, GA and CS, were on the medium.  
On the left hand, nanopaticles shape was perceived with more detail. Besides, it was also 
possible to recognize GoldNP inside and/or in the surface of nanoparticles, what confirmed the 
results of encapsulation efficiency. 
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4.4. Vitamin D/Gold NP-loaded CS/GA nanoparticles 
 
4.4.1. Size, zeta potential and encapsulation efficiency 
 
The same preparation of CS/GA was also tested for encapsulation of vitamin D with GoldNP. 
The physicochemical characterization obtained are presented in Table 10. Furthermore, the 
encapsulation results are shown in Table 11. 
 
Table 10.  Physicochemical characterization for uncoated and coated by polysorbate80 nanoparticles with 
different conditions of vitamin D and GoldNP. Data represented as mean ± SD. 
Drug-loaded [-] Cp80 [% v/v] dm [nm] PdI [-] ZP [mV] 
Vit. D 0.0 277 ± 4 0.3 ± 0.05 34 ± 7 
Vit. D 1.0 294 ± 9 0.3 ± 0.08 38 ± 3 
Vit. D + AuNP(PEG) 0.0 383 ± 6 0.3 ± 0.04 41 ± 3 
   Vit. D + AuNP(PEG) 1.0 469 ± 12 0.5 ± 0.06 44 ± 3 
 
 
Table 11. Vitamin D and GoldNP encapsulation efficiency and loading capacity with different 
combination of EGCG and GoldNP – CS/GA nanoparticles. Data represented mean ± SD.  
  
Vitamin D AuNP (PEG) 
Time loaded [min] Cp80 [% v/v] En.Eff. [%] Load. C. [%] En.Eff. [%] Load. C. [%] 
Vit. D 0.0 77 ± 5 4.6 ± 5.2 - - 
Vit. D 1.0 96 ± 2 8.8 ± 1.4 - - 
Vit. D + AuNP(PEG) 0.0 76 ± 5 4.8 ± 3.5 100 ± 0 1.3·10
-6
± 0.0·10
-6
 
Vit. D + AuNP(PEG) 1.0 82 ± 7 6.9 ± 1.8 100 ± 0 1.2·10
-6
± 0.0·10
-6
 
 
 
As it has been appreciated in Table 10, in case of vitamin D was prepared vitamin D CS/GA 
nanoparticles and Vitamin D and GoldNP CS/GA nanoparticles. In both preparations it was 
tested coating the nanoparticles surface by adding polysorbate 80.  
Focusing in results, nanoparticles with just vitamin D decreased the mean diameter compare to 
CS/GA nanoparticles in the same CS and GA concentrations. However, the zeta potential also 
decreased resulting in less stable particles. On the other hand, the size of vitamin D and GoldNP 
CS/GA nanoparticles became higher than the CS/GA nanoparticles related to this case. The zeta 
potential is slightly lower.  
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Even so, in general, it was observed that presence of polysorbate 80 resulted in a higher mean 
diameter. But increased, as well,  the zeta potential, improving the nanoparticles stability.  
Generally, the results showed satisfactory vitamin D encapsulation efficiency. In addition, it 
was observed that encapsulation of vitamin D did not change with the presence of GoldNP. 
Nevertheless, the encapsulation efficiency increased in both cases with the presence of 
polysorbate 80 on their surface. GoldNP encapsulation efficiency it was complete in 
concentration testes with uncoated and coated nanoparticles.  
 
4.4.2. Morphologic analysis 
 
TEM image, Figure 18, that represents the vitamin D and GoldNP CS/GA coated nanoparticles.  
 
 
 
 
 
 
 
 
Figure 18. TEM micrographs of vitamin D and GoldNP-CS/GA coated nanoparticles The scalebar 
correspond to 200 nm on left. 
 
First of all, indicate that probably there were some problems during the staining of the sample in 
the carbon coated copper TEM grid, as it was appreciate after.  
Despite this, relative spherical shape of nanoparticles was observed, as well as the GoldNP 
which were shown inside the nanoparticles. Also, it was noted the polysorbate 80 in the surface 
of nanoparticles. 
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5. Conclusions and Future Perspectives 
 
5.1. Conclusions 
 
Nanotechnology has been developed as a powerful tool for cancer drug delivery, to reduce the 
side effects and large toxic doses with the traditional chemotherapy. Nanoparticles seem to 
present numerous advantages over usual anticancer drugs, such as more effective and controlled 
release into the specific target, as well as, increasing their solubility, protecting them from the 
macrophage uptake and improving their time life. Due to the characteristics of polysaccharides, 
nanoparticles matrix made of them presents favorable properties, such as biocompatibily, 
biodegradability and water solubility.   
In this work, chitosan nanoparticles were prepared by polyelectrolyte complexation upon the 
addition of a negatively charged polymer, gum arabic. Its negatively charged carboxylic groups 
interact with positive amine groups of chitosan.  
At first, physicochemical and morphologic characterization of bare nanoparticles, modifying 
their concentration and their mass concentration ratio allowed to select the optimal values for 
the different parameters and obtaining the optimal nanoparticles for the drug encapsulation. The 
bare CS/GA nanoparticles presented a mean diameter of 300 nm, low polydispersity and a 
positive zeta potential. TEM images confirmed those results and showed a spherical and 
dispersed nanoparticles. 
Loaded nanoparticles achieved satisfactory results for encapsulation efficiency. The 
encapsulation of bortezomib in CS/GA system reached values of 52% while if bortezomib was 
encapsulated together with GoldNP this value increased to 65%. GoldNP encapsulation was 
nearly total. When these particles were coated with polysorbate 80, the size increased but the 
stability and the encapsulation efficiency of bortezomib reached values of 70%.  
As it was appreciate by TEM images, GoldNP were inside or/and on the surface of 
nanoparticles as well as, it was observed polysorbate80 around the surface of nanoparticles, 
what explained the higher mean diameter values.  
The release profile of bortezomib in CS/GA nanoparticles and in GoldNP CS/GA nanoparticles 
was different as compared to the free drug, showing a biphase pattern. First, free drug released 
100% in water while the encapsulated one attained till the 50%. On the other hand, in PBS, the 
degradation of the nanoparticles in 4-5h and faster release for the free bortezomib were 
observed. 
The cytotoxic studies in pancreatic cancer cells revealed the non-toxicity of CS/GA 
nanoparticles and GoldNP CS/GA nanoparticles, but probably the negative effect of 
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polysorbate80 on that concentration. The concentration-response studies showed the higher 
toxicity for the free bortezomib, compared with the encapsulated one, even the BTZ CS/GA 
nanoparticles had certain toxicity. Important results were obtained also in normal cells, while 
free bortezomib produced the death of normal cells too, the encapsulated bortezomib just 
inhibited their growth at the same concentration range that had better response in pancreatic 
cells.  
Despite being necessary further studies, it seemed that encapsulated bortezomib presents 
enormous advantages of its selectively for the target cancer cells even the necessity of prevent 
drug from degradation.  
The other formulation with chemopreventive agents tested gave as well successful results, 
confirming the adequate concentrations of CS and GA chosen at the beginning. The 
nanoparticles presented a size between 200-400 nm, low polydispersity and positive zeta 
potential. The encapsulation of EGCG and GoldNP in CS/GA system reached values of 36%, 
while the coated ones, increased to 46%. In respect to vitamin D, encapsulated together with 
GoldNP or not, the efficiency of encapsulation was 75%, and reached values of 90% for the 
coated particles with polysorbate80. In both agents, nanoparticles that contain GoldNP, coated 
and uncoated, the encapsulation efficiency of it was around 100%.  
Overall, with the obtained results it is possible to conclude that CS/GA nanosystem is rapidly 
produced and it is a good candidate for the target delivery of the anticancer drug bortezomib 
with or without GoldNP in the treatment of pancreatic cancer allowing the use of lower 
concentrations of drug. In addition, this system presented satisfactory results for the 
encapsulation of chemopreventive agents, EGCG and vitamin D, with GoldNP which could 
allow their easily administration.     
 
 
5.2. Future perspectives 
 
In order to confirm and improve this system additional experiences could be important as 
described below. Several tests have not been carried out due to time restrictions. 
The CS/GA nanoparticles seemed to be an approach to reduce and control the release of the 
anticancer drug bortezomib, although further experiments are required in order to confirm and 
complete the obtained results.  
Some studies to verify the stability of the nanoparticles in temperature and pH conditions 
similar to that of human cells, as well as their time life in that conditions. Other parameters like 
bortezomib loaded concentration may be interesting to be tested in order to obtain better 
physicochemical characteristics and reaching higher levels of encapsulation with lower 
concentrations of drug. As well as, to optimize the concentration of polysorbate 80 or another 
surfactant that stabilizes the nanoparticles but does not produce toxicity in cells.  
Process final yield, FTIR, NMR and DSC studies should be performed to investigate and 
characterize the bortezomib entrapment and the state of the drug inside the nanoparticles.  
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Moreover, other release studies at body temperature and similar medium as blood should be 
carried out. More studies in PBS should be carried out in order to confirm the biodegradability 
results. Furthermore, more complete cytotoxic studies should be performed in order to 
determine the action of GoldNP and their beneficial presence together with bortezomib. 
Additionally, cytotoxic studies for the EGCG and vitamin D loaded nanoparticles as well as 
release studies must be performed to know their behavior and benefits in cancer and normal 
cells. 
Continuing to more advanced stages of investigation, in vivo anti-tumor test, pharmacokinetics 
and mucoadhesion studies, as well as, biodistribution and histological observation of the studied 
cancer tissues must be performed.     
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